| |
 |
|
|
| Jointly presented by The Johns Hopkins University School of Medicine, AKH Inc., Advancing Knowledge in Healthcare, and Advanced Strategies in Medicine. |
| |
 |
| |
 |
| |
 |
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine, AKH Inc., and Advanced Strategies in Medicine. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
 AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
AKH Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP12070, for 1.0 contact hour.
Credit Designation
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. has approved this pharmacist educational activity for 1.0 contact hour UPN077-999-08-005-L01-P. Initial Release Date: 6/11/2008
AKH Inc. designates this nurse educational activity for 1.0 contact hour (0.10 CEU).
The Johns Hopkins University School of Medicine and AKH Inc. take responsibility for the content, quality, and scientific integrity of this CE activity.
Credit is awarded to participants who listen to each presentation, complete the activity evaluation, and self-report credit form. Partial credit is not available to nurse and pharmacist participants. Statements of credit will be mailed within 6-8 weeks of the program date. There is no fee to participate. |
| |
| Supported by an educational grant from Cephalon Oncology, Cephalon, Inc. |
|
|
|
|
Calls scheduled June 11 - June 25, 2008
Click Here to Register Now
|
| COURSE DIRECTOR |
|
|
Judith E. Karp, MD
Director, Adult Leukemia Program
Division of Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University
School of Medicine
Baltimore, Maryland |
| |
|
| FACULTY |
|
|
James O. Armitage, MD
Professor, Internal Medicine
Section of Hematology/Oncology
University of Nebraska Medical Center
Omaha, Nebraska |
|
Ian W. Flinn, MD, PhD
Director, Hematologic Malignancy Research
Sarah Cannon Research Institute and
Tennessee Oncology
University of Tennessee Health Science Center
Knoxville, Tennessee |
|
Julie M. Vose, MD
Neumann M. and Mildred E. Harris Professor
Chief, Section of Hematology/Oncology
Professor of Medicine
Nebraska Medical Center
Omaha, Nebraska |
| |
| POLICY ON FACULTY AND
PROVIDER DISCLOSURE |
|
|
| It is the policy of The Johns Hopkins University School of Medicine and AKH Inc. that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME and AKH Inc. have established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials. |
|
|
| |
| AMERICANS WITH
DISABILITIES ACT (ADA) |
|
|
| The Johns Hopkins University School of Medicine and AKH Inc. fully comply with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs. |
|
| |
|
|
| PROGRAM DESCRIPTION |
|
|
| The primary objective of this program is to provide oncologists, pharmacists, and oncology nurses with current and clinically relevant information about the diagnosis, classification, and optimal multidisciplinary management of non-Hodgkin lymphoma (NHL), and to help these clinicians improve the quality of care they provide to their patients. Following a case-based format, the presentations are intended to illustrate best practices in the diagnosis and management of NHL. |
|
| |
| TARGET AUDIENCE |
|
|
| This program is intended for physicians, pharmacists, and nurses who treat patients with hematologic malignancies. There are no prerequisites for this educational program. |
|
| |
| LEARNING OBJECTIVES |
|
|
| At the conclusion of this activity, participants
should be able to: |
|
| • |
Review recent advances in molecular diagnostic strategies for NHL |
|
| • |
Describe the aberrant signal transduction pathways underlying NHL |
|
| • |
Compare and contrast current treatment strategies for patients with NHL |
|
| • |
Discuss results from recent studies on investigational treatment strategies for NHL |
|
| • |
Describe the mechanisms by which current and emerging chemotherapeutic and biologic therapies achieve their antineoplastic effects |
|
The teleconference will include a didactic case-based presentation followed by an interactive question and answer session.
The Johns Hopkins University School of Medicine and AKH Inc. take responsibility for the content, quality, and scientifc integrity of this CE activity. |
|
|
| |
|
|
| WAYS TO REGISTER |
|
|
|
• |
You may register online by clicking here |
| |
• |
You may send an e-mail to oncologytelecon2@mcmahonmed.com
Please include your name, address, and your phone and fax numbers |
| |
• |
Should you have any questions regarding this program, please call (866) 408-3732 |
|
|
|
|
|
